НОВЫЕ ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ И АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА В ЛЕЧЕНИИ ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ

1. Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep vein thrombosis // Lancet. 2012. №379. Р. 1835–1846.

2. Spencer F.A., Emery C., Lessard D. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism // J. Gen Intern. Med. 2006. №21. Р. 722–727.

3. Christiansen S.C., Cannegieter S.C., Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events // JAMA. 2005. №293. Р. 2352–2361.

4. Kearon C., Akl E.A., Comerota A.J. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed.: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012. №141. Suppl. Р. e 419S– e 494 S.

5. Eriksson B.I., Dahl O.E., RosencherN. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial // J. Thromb. Haemost. 2007. №5. Р. 2178–2185.

6. Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial // Lancet. 2007. №370. Р. 949–956.

7. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009. № 361. P. 1139–1151.

8. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism // N. Engl. J. Med. 2009. №361. Р. 2342–2352.

9. Turpie A.G., Lassen M.R., Eriksson B.I. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies // Thromb. Haemost. 2011. №105. Р. 444–453.

10. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011. №365. Р. 883–891.

11. Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome // N. Engl. J. Med. 2012. №66. Р. 9–19.

12. Buller H.R., Lensing A.W.A., Prins M.H. et al. A doseranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study // Blood. 2008. №112. Р. 2242–2247.

13. Agnelli G., Gallus A., Goldhaber S.Z. et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study // Circulation. 2007. №116. Р. 180–187.

14. Barritt D.W., Jordan S.C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial // Lancet. 1960. №1. Р. 1309–1312.

15. The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease // N. Engl. J. Med. 2007. №357. Р. 1094–1104.

16. Brandjes D.P.M., Heijboer H., Buller H.R. et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis // N. Engl. J. Med. 1992. №327. Р. 1485–1489.

17. Fiessinger J.N., Huisman M.V., Davidson B.L. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial // JAMA. 2005. №293. Р. 681–689.

18. Mueck W., Lensing A.W., Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention // Clin. Pharmacokinet. 2011. №50. Р. 675–686.

19. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism // N. Engl. J. Med. 2010. №363. Р 2499–2510.

20. The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism // N. Engl. J. Med. 2012. №366. Р. 1287–1297.

21. Schafer A.I. Venous thrombosis as a chronic disease // N. Engl. J. Med. 1999. №340. Р. 955–956.

22. Prandoni P., Lensing A.W., Cogo A. et al. The longterm clinical course of acute deep venous thrombosis //Ann. Intern. Med. 1996. №125. Р. 1–7.

23. Schulman S., Rhedin A-S., Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism // N. Engl. J. Med. 1995. №332. Р. 1661–1665.

24. Agnelli G., Prandoni P., Santamaria M.G. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis // N. Engl. J. Med. 2001. №345. Р. 165–169.

25. Agnelli G., Prandoni P., Becattini C. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism // Ann. Intern. Med. 2003. №139. Р. 19–25.

26. Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism // N. Engl. J. Med. 1999. №340. Р. 901–907.

27. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2011. №365. Р. 981–992.

28. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation // N. Engl. J. Med. 2011. №364. Р. 806–817.

29. Raskob G.E., Gallus A.S., Pineo G.F. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials // J. Bone. Joint Surg. Br. 2012. №94. Р. 257–264.

30. Agnelli G., Buller H.R., Cohen A. et al. for the AMPLIFY- EXT Investigators. Apixaban for Extended Treatment of Venous Thromboembolism // N. Engl. J. Med. 2013. №368. Р. 699–708.

31. Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis // Lancet. 1980. №2. Р. 1328–1329.

32. Becattini C., Agnelli G., Schenone A. et al. Aspirin for Preventing the Recurrence of Venous Thromboembolism // N. Engl. J. Med. 2012. №366. Р. 1959–1967.

33. Brighton T.A., Eikelboom J.W., Mann K. et al. Low- Dose Aspirin for Prevention Recurrent Venous Thromboembolism // N. Engl. J. Med. 2012. №367. Р. 1979–1987.

34. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients // BMJ. 1994. №308. Р. 235–246.

35. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial // Lancet. 2000. №355. Р. 1295–1302.

36. Grady D., Wenger N.K., Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study // Ann. Intern. Med. 2000. №132. Р. 689–696.

37. Becattini C., Agnelli G., Prandoni P. et al. A prospective study on cardiovascular events after acute pulmonary embolism // Eur. Heart. J. 2005. №26. Р. 77–83.

38. Patrono C., Baigent C., Hirsh J., Roth G. Antiplate let drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008. №133. Suppl. Р. 199 S–233 S.

39. Linkins L.A., Choi P.T., Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for with venous thromboembolism: a meta-analysis // Ann. Intern. Med. 2003. №139. Р. 893–900.

40. Ridker P.M., Goldhaber S.Z., Danielson E. et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism // N. Engl. J. Med. 2003. №348. Р. 1425–1434.

41. Kearon C., Ginsberg J.S., Kovacs M.J. et al. Comparison of low-intensity warfarin therapy with conventional- intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism // N. Engl. J. Med. 2003. №349. Р. 631–639.

42. Schulman S., Eriksson H., Goldhaber S.Z. et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism // J. Thromb. Haemost. 2011. №9. Suppl. 2. Р. 731–732.

43. Schulman S., Baanstra D., Eriksson H. et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism // J. Thromb. Haemost. 2011. №9. Suppl. 2. Р. 22–22.

44. Воробьева Н.М., Панченко Е.П., Ермолина О.В. и др. Продление терапии эноксапарином до одного месяца способствует реканализации окклюзивно тромбированных глубоких вен // Терапевтический архив. 2011. Т. 83. №8. С. 33–37.

45. Воробьева Н.М., Панченко Е.П., Добровольский А.Б. [и др.] Независимые предикторы рецидива тромбоза глубоких вен (результаты проспективного 18-месячного наблюдения) // Кардиология. 2010. Т. 50. №12. С. 52–58.